Funding
Series C · Biotech

AusperBio raises $120M Series C

AusperBio raised $120 million in Series C financing announced in August.

Updated Oct 16, 2026By RoundOS Funding desk

RA Capital Management, HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments are among its investors.

The company develops oligonucleotide therapeutics targeting chronic hepatitis B.

Funding history

Series C · This round$120M

Sources

  1. AusperBioprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related